
Active investigation
Diagnosed with a brain tumor after the Depo-Provera shot?
Claims allege the Depo-Provera shot raises the risk of meningioma, and that U.S. patients were never warned. You may be entitled to compensation.

The Depo-Provera claim explained
Video slot
- Free, confidential claim review
- No up-front cost, you pay nothing unless you win
- Most callbacks within 15 minutes
- Two minutes to complete the form
What the claims are about
Depo-Provera (medroxyprogesterone acetate) is a contraceptive injection given roughly every three months. Research published in 2024 reported that prolonged use of the drug was associated with a meaningfully increased risk of intracranial meningioma. Product labeling in some countries outside the United States had carried a meningioma warning for years. Lawsuits now allege that U.S. patients and their doctors were never given that same warning, and that a safer or better-labeled alternative would have changed their decision to use the shot.
What plaintiffs allege
A known risk, allegedly not disclosed here
Plaintiffs allege the manufacturer was aware of published research connecting long-term medroxyprogesterone acetate use to meningioma, yet U.S. labeling did not carry the warning that appeared on the product elsewhere.
No chance to weigh the risk
The claims argue that patients and prescribing physicians could not weigh a risk they were never told about, and would have considered other contraceptive options had they known.
Years of repeat exposure
Because the injection is typically repeated every three months over years, the alleged risk compounds with each dose, which is central to how these claims are being evaluated.
Diagnoses connected to these claims
Claims generally involve a tumor diagnosis after repeated use of the injection, particularly where treatment was required.
- Intracranial meningioma
- Brain tumor requiring surgical removal (craniotomy)
- Brain tumor treated with radiation or radiosurgery
- Tumor under active monitoring after imaging
- Related complications: vision loss, seizures, persistent headaches, hearing loss
You may qualify if
- Received Depo-Provera or its generic equivalent, generally for a year or longer
- Diagnosed afterward with a meningioma or other brain tumor
- The diagnosis was confirmed by imaging such as an MRI or CT scan
- Treatment involved surgery, radiation, or ongoing monitoring
Time is limited, and it takes a couple of minutes to see if you qualify
- 01
Complete the form
Answer a few short questions. It takes about two minutes and costs nothing.
- 02
Get a free claim review
A claims specialist calls to discuss your situation and collect the details needed to evaluate your claim.
- 03
Pursue compensation
If you qualify, you are connected with an attorney who fights for the compensation you deserve.
Common questions
How long did I need to be on the shot to have a claim?
There is no single cutoff, but these claims generally focus on repeated use over about a year or more. If you used the injection for a shorter period and were later diagnosed, it still costs nothing to have your situation reviewed.
I used the generic version, not the brand. Does that matter?
It may affect how a claim is handled, but generic medroxyprogesterone acetate injections are being reviewed as well. Mention it during your claim review.
Is there a deadline to file?
Yes. Every state limits how long you have to bring a claim, and those deadlines can run from the date of diagnosis. Waiting is the most common reason people lose the ability to file at all.
What does it cost me?
Nothing to have your claim reviewed. If you are connected with an attorney and choose to move forward, these claims are handled on a contingency basis, meaning the attorney is paid only out of a recovery.
Other active claims
Active investigationTalcum Powder
Claims allege long-term talc-based body powder use is linked to ovarian cancer and mesothelioma, without adequate warning to consumers.
Active investigationHair Straightener & Relaxer
A 2022 NIH study found frequent users of chemical hair straighteners were more than twice as likely to develop uterine cancer.
Active investigationHernia Mesh
Mesh products are linked to migration, adhesion, infection and failure, with revision surgery often the only fix.
This page describes allegations made in pending litigation. Allegations are not findings of fact, and no outcome is guaranteed. Prior results do not guarantee a similar outcome. Information last reviewed August 2026.
